Viking Therapeutics Inc
Cerrado
SectorSanidad
32.01 -2.11
Resumen
Variación precio
24h
Mínimo
31.78
Máximo
32.69
Ingresos | 30M -128M |
|---|---|
BPA | -1.1 |
Empleados | 65 |
EBITDA | 30M -128M |
Próximas Ganancias | 21 oct 2026 |
|---|
Capitalización Mercado | 19M 4.1B |
|---|---|
Apertura anterior | 34.12 |
Cierre anterior | 32.01 |
Noticias sobre sentimiento de mercado
By Acuity
50%
50%
144 / 339 Clasificación en Healthcare
Viking Therapeutics Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Viking Therapeutics Inc previsión
Sentimiento
By Acuity
144 / 339 Clasificación en Sanidad
Noticias sobre sentimiento de mercado
Neutral
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.